Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Recruiting 4Not yet recruiting 1Enrolling by invitation 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Interventional 5Observational 3

Sponsor

Cancer Type

Breast 8

Conditions

Breast Neoplasms 2315Neoplasms 1678Prostatic Neoplasms 1178Lung Neoplasms 908Colorectal Neoplasms 873Carcinoma, Non-Small-Cell Lung 848Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 510Brain Neoplasms 509Neoplasm Metastasis 456Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 397Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 355Squamous Cell Carcinoma of Head and Neck 355Rectal Neoplasms 336Recurrence 332Hematologic Neoplasms 323Sarcoma 322Colonic Neoplasms 316Lymphoma 310Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Glioma 277Carcinoma, Renal Cell 277

Interventions

Fulvestrant 2trastuzumab deruxtecan 1sacituzumab govitecan 1ribociclib 1pegfilgrastim 1abemaciclib 1Zoledronic Acid 1Paclitaxel 1Neoadjuvant Therapy 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
OTHER × Breast Cancer Metastatic × 1 year × Clear all
NCT07586215 2026-05-14

PREDICT-HER

Fudan University

Recruiting
100 enrolled
Breast

Breast Cancer Metastatic

NCT06750484 2026-05-06

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Yale University

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT06706570 2026-03-24

PIK3CA Mutational Status Assessment

European Institute of Oncology

Recruiting
100 enrolled
Breast

Breast Cancer Metastatic

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Samsung Medical Center

Phase 2 Not yet recruiting
272 enrolled
Breast

Breast Cancer Metastatic

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed
162 enrolled
Breast

Breast Cancer Metastatic

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT06876636 2025-07-29

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

Xijing Hospital

Phase NA Active not recruiting
99 enrolled
Breast

Breast Cancer Metastatic

NCT06914661 2025-07-08

EASOFDIMBCT

The First Hospital of Jilin University

Enrolling by invitation
200 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡